Feature | August 19, 2013

Medtronic Submits Drug-Eluting Balloon for FDA Review

Vendor hopes for pre-market approval for novel peripheral angioplasty device in second half of 2015

August 19, 2013 — Medtronic Inc. announced the submission of its first pre-market approval (PMA) module to the U.S. Food and Drug Administration (FDA) for the IN.PACT Admiral drug-eluting balloon. Designed to treat atherosclerotic lesions in the superficial femoral artery (SFA), the novel angioplasty device remains investigational in the United States.

“Pending FDA approval, we remain on track to launch the IN.PACT Admiral drug-eluting balloon in the United States during the second half of calendar year 2015,” said Tony Semedo, president of Medtronic’s Endovascular Therapies business. “In the meantime, we will continue working with leading healthcare providers and researchers around the world to amass clinical and economic evidence to support the global adoption of this innovative medical technology as an important addition to the treatment options for peripheral artery disease in the lower extremities.”

The ongoing global clinical program of IN.PACT drug-eluting balloons for the treatment of peripheral artery disease (PAD) in the lower extremities includes 24 studies involving more than 4,200 patients at approximately 230 sites worldwide. A combination of physician-initiated and company-sponsored studies, the program will fully characterize the safety and efficacy of these combination devices in a variety of peripheral vascular beds, including below-the-knee arteries.

Medtronic’s PMA application for the IN.PACT Admiral drug-eluting balloon will include clinical data from the IN.PACT SFA I and SFA II pivotal studies, the IN.PACT SFA II pharmacokinetics (PK) study, and the IN.PACT Global study, which have enrolled a total of more than 1,000 patients to date.

IN.PACT drug-eluting balloons feature a proprietary coating called FreePac that is a formulation of the antiproliferative drug paclitaxel and the biocompatible excipient urea, which facilitates rapid absorption of the drug into the vessel wall.

Several IN.PACT drug-eluting balloons received CE mark in 2008 and 2009 and are available in many countries around the world. In the United States, the IN.PACT Admiral drug-eluting balloon is limited to investigational use, and, like all drug-eluting balloons, is not yet commercially available.

The treatment of PAD varies by stage of progression and other factors, with lifestyle modifications aimed at risk factor reduction recommended for all stages. Drug-eluting balloons represent a relatively recent addition to the procedural approaches, which also include atherectomy, balloon angioplasty and stenting. In cases involving especially long lesions, bypass surgery can create a new route for blood flow around the diseased artery.

For more information: www.medtronic.com

Related Content

Virtue Sirolimus-Eluting Balloon Demonstrates Positive Safety and Efficacy at Three Years
News | Drug-Eluting Balloons | September 25, 2018
Orchestra BioMed Inc. announced the three-year clinical results from its Sirolimus Angioplasty Balloon for In-Stent...
Three-Year Real-World Data Support In.Pact Admiral as Primary PAD Therapy
News | Drug-Eluting Balloons | September 24, 2018
 New data announced at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego,...
FDA Approves 200, 250 Millimeter In.Pact Admiral Drug Coated Balloons
Technology | Drug-Eluting Balloons | June 15, 2018
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for 200mm and 250mm lengths of the In.Pact...
News | Drug-Eluting Balloons | May 29, 2018
M.A. MedAlliance SA has raised $37 million to help develop and commercialize the first sirolimus micro-reservoir drug-...
In.Pact Admiral Balloon Demonstrates Consistent, Durable Outcomes in LINC 2018 Studies
News | Drug-Eluting Balloons | February 07, 2018
Medtronic plc recently added to its body of clinical evidence supporting the In.Pact Admiral drug-coated balloon (DCB)...
The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

Feature | Drug-Eluting Balloons | November 02, 2017
November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons | September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval
Technology | Drug-Eluting Balloons | August 29, 2017
C.R. Bard Inc. announced the Lutonix 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (...
Overlay Init